Loading
Locally Advanced Pancreatic Cancer / Pancreatic Neoplasms / Antineoplastic Combined Chemotherapy Protocols · Journal article
Journal of Medical Economics · July 28, 2026
Reinforces what was already believed, rather than introducing something new.
TTFields plus chemotherapy increased lifetime costs by $131,400 while generating 0.34 discounted QALYs, yielding an ICER of $387,300 per QALY—substantially above the conventional $100,000–$150,000 U.S. threshold. The analysis demonstrates measurable quality-of-life benefit (0.03 QALYs from reduced pain progression) alongside survival gains, which the authors argue should inform interpretation in the context of a disease with high unmet medical need and limited alternatives.
Cost-utility analysis based on partitioned survival model. Intent-to-treat population from PANOVA-3 trial of locally advanced pancreatic cancer patients receiving first-line treatment.. Intervention: Tumor Treating Fields (TTFields) therapy applied with gemcitabine plus nab-paclitaxel (GnP). Compared with: Gemcitabine plus nab-paclitaxel (GnP) alone.
TTFields + GnP increased discounted lifetime costs to $351,400 versus $220,000 for GnP alone. Incremental gain of 0.34 QALYs with an ICER of $387,300 per QALY gained. Approximately 0.03 QALYs attributable to reduced time lived with pain.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians and payers should recognize that TTFields + chemotherapy delivers measurable survival and quality-of-life improvements in a disease with poor prognosis and limited options, though the ICER exceeds traditional cost-effectiveness thresholds. The pain-progression benefit may carry disproportionate value for patients with locally advanced disease experiencing high symptom burden.
Cost-utility analysis of a novel cancer therapy showing incremental QALY gain with high ICER; confirms clinical benefit translates to measurable quality-of-life improvement but at costs above conventional thresholds.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians and payers should recognize that TTFields + chemotherapy delivers measurable survival and quality-of-life improvements in a disease with poor prognosis and limited options, though the ICER exceeds traditional cost-effectiveness thresholds. The pain-progression benefit may carry disproportionate value for patients with locally advanced disease experiencing high symptom burden.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background. Locally advanced pancreatic cancer (LAPC) is associated with limited survival, high symptom burden, and few therapeutic innovations. The PANOVA-3 trial evaluated Tumor Treating Fields (TTFields) therapy applied with gemcitabine plus nab-paclitaxel (GnP) for first-line treatment of LAPC, demonstrating improved overall survival (OS), distant progression-free survival (PFS), and time to pain progression. We conducted a cost-utility analysis to evaluate the economic value of TTFields + GnP relative to GnP alone.Methods. A partitioned survival model was developed using trial-based Kaplan-Meier curves for OS, distant progression-PFS, and time to pain progression. Model inputs reflected the intent-to-treat (ITT) population from PANOVA-3, with health utilities, resource use, and costs obtained from published U.S. sources. Disutility for pain was applied during time after pain worsening to capture quality-of-life decrement. Costs and outcomes were discounted at 3% annually, and analyses were conducted from a U.S. payer perspective. Deterministic, probabilistic, and scenario analyses explored uncertainty in key assumptions and model structure.Results. TTFields + GnP increased discounted lifetime costs to $351,400 vs. $220,000 for GnP alone, with an incremental gain of 0.34 QALYs and an ICER of $387,300 per QALY. Approximately 0.03 QALYs were attributable to reduced time lived with pain. Sensitivity analyses identified TTFields therapy cost and treatment duration as primary drivers of the ICER. Scenario analyses produced ICERs ranging from $391,800 to $547,200 per QALY.Conclusions. TTFields + GnP improves survival and delays pain progression in LAPC, generating measurable gains in quality-adjusted survival. Resulting ICERs should be interpreted in the context of a disease with high unmet need, poor prognosis, and limited therapeutic options; factors that support a broader assessment of value beyond conventional cost-effectiveness thresholds. The multidimensional benefits observed, including quality-of-life gains, reinforce the case for TTFields therapy in LAPC and highlight the importance of incorporating such endpoints into economic evaluations of late-stage cancers.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.